Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Nov 26, 2013	Evoke Pharma Selects SynteractHCR as Contract Research Organization for Phase 3 Trial of EVK-001 for Gastroparesis SAN DIEGO , Nov. 26, 2013 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the selection of SynteractHCR, Inc. to serve as its primary contract research organization ("CRO") for its	View HTML Evoke Pharma Selects SynteractHCR as Contract Research Organization for Phase 3 Trial of EVK-001 for Gastroparesis 17.1 KB
Toggle Summary Nov 09, 2017	Evoke Pharma Signs Commercial Agreement with Thermo Fisher Scientific SOLANA BEACH, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the selection of the Patheon division of Thermo Fisher Scientific, Inc., as the commercial	View HTML Evoke Pharma Signs Commercial Agreement with Thermo Fisher Scientific 17.3 KB
Toggle Summary Jan 07, 2019	Evoke Pharma Signs Commercial and Financial Agreement for its Lead Product Gimoti™ in the U.S. with Novos Growth Partners Novos to provide fully integrated commercial function for Evoke and non-dilutive financing for the commercialization of Gimoti, extending cash runway into 2020 Evoke will retain greater than 80% of product profits following approval SOLANA BEACH, Calif. , Jan.	View HTML PDF Version
Toggle Summary Dec 02, 2013	Evoke Pharma Strengthens Executive Team With Appointments of Chief Medical Officer and Senior Director of Clinical Operations Experienced Clinical Executives to Drive Phase 3 Trial of EVK-001 for Gastroparesis	View HTML Evoke Pharma Strengthens Executive Team With Appointments of Chief Medical Officer and Senior Director of Clinical Operations 18.3 KB
Toggle Summary Oct 07, 2015	Evoke Pharma Strengthens Financial Position Provides Additional Support for Completion of Phase 3 Trial and Submission of New Drug Application (NDA)	View HTML Evoke Pharma Strengthens Financial Position 16.9 KB
Toggle Summary Nov 30, 2022	Evoke Pharma Strengthens its Intellectual Property Portfolio with a Notice of Allowance from the USPTO for a Patent Application Related to GIMOTI® SOLANA BEACH, Calif. , Nov. 30, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced the United States Patent and	View HTML PDF Version
Toggle Summary Jan 22, 2014	Evoke Pharma Study Reports Positive Results of Metoclopramide Nasal Spray for Gastroparesis in Diabetics SAN DIEGO , Jan. 22, 2014 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the publication of a study that found intranasal delivery of metoclopramide to be more effective in managing	View HTML Evoke Pharma Study Reports Positive Results of Metoclopramide Nasal Spray for Gastroparesis in Diabetics 16 KB
Toggle Summary Mar 14, 2019	Evoke Pharma Submits Response to FDA Review Letter for Gimoti™ NDA Meeting with FDA scheduled for March 21, 2019 SOLANA BEACH, Calif. , March 14, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has submitted its response to the U.S.	View HTML PDF Version
Toggle Summary Jan 09, 2017	Evoke Pharma to Attend 2017 JPMorgan Healthcare Conference SOLANA BEACH, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer, and its Chief Business Officer, Matt	View HTML Evoke Pharma to Attend 2017 JPMorgan Healthcare Conference 14.7 KB
Toggle Summary Jun 14, 2023	Evoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its Treatment Study between nasal and oral metoclopramide selected by Digestive Disease Week (DDW) 2023 faculty for plenary presentation SOLANA BEACH, Calif. , June 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for	View HTML PDF Version